HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer

摘要: Human epidermal growth factor receptor 2 (HER2) plays an important role in breast cancer progression and provides predictive information for response to targeted therapy including trastuzumab although this is limited. Downstream pathways, such as PI3K/Akt, are associated with HER2/HER3 heterodimerization promoting survival proliferation amongst cells. Thus, patient outcome effectiveness might be further characterised by dimerisation its signalling pathways. status was assessed, using chromogenic situ Proximity Ligation Assay, two series: early stage primary cancer, 224 HER2+ patients that were not submitted trastuzumab, where treated adjuvant (n = 143). Levels of biomarkers PI3K, pAKT, ER, PgR, HER3, BCL2, p53, PTEN p21 measured immunohistochemistry. heterodimers compared biomarker expression outcome. An association between high levels absence hormone receptors, ER was observed. We show the first time presence loss predicts a significantly poorer when trastuzumab. Breast reveal poor prognosis Further quantification analysis HER dimer/ligand complexes downstream pathways will begin unravel complex associations relationship sensitivity treatment.